IONS · Ionis Pharmaceuticals, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $6.67B |
| P/E | — |
| Float | 164.4M |
| Beta | 0.36 |
| Volatility 30D | 36.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 66.3 |
| Price | 38.60 |
| Change | −3.86% |
| Prev Close | 40.15 |
| Open | 41.38 |
| Day Low | 39.33 |
| Day High | 41.52 |
| Avg Vol | 3 |
| Avg $ Vol | $110.5M |
| 52W High | 86.74 |
| 52W Low | 40.15 |
| 52W Pos | −3.3% |
| From High | −55.50% |
| From Low | −3.86% |
| Max DD 1Y | −53.58% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −10.99% |
| SMA 50 | −19.16% |
| SMA 200 | −41.73% |
| RSI (14) | 33.5 |
| Vol 90D | 63.0% |
| Vol 1Y | 44.9% |
| 1Y Range | 40–87 |
| Daily bars | 549 |
| Perf Week | −10.58% |
| Perf Month | −8.75% |
| Perf Quarter | −26.32% |
| Perf Half Y | −47.76% |
| Perf Year | −45.49% |
| Perf YTD | −51.55% |
| Prev Day | −3.86% |
| Clavix | B- |
| Debt / Eq | 3.71 |
| Curr Ratio | 3.83 |
| Int Cover | -8.4× |
| FCF Margin | −33.9% |
| Rev Growth | +33.8% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 23 / 35 |
Clavix risk grade
regraded every trading dayIONS grades B-, 66.3 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (45, fragile). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 23 of 35 in Biotechnology by Clavix score.
How rough the ride is
| IONS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.36 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 36.9% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −53.6% | — |
| Typical daily movemedian absolute daily change | 1.45% | — |
| Days beyond ±3%of the last 252 sessions | 41 (16%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| IONS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.36 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| IONS | |
|---|---|
| 1 week | −10.6% |
| 1 month | −8.8% |
| Year to date | −51.6% |
| 1 year | −45.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| IONS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Sep |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 8 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 8 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| IONS | |
|---|---|
| Revenue growthyear over year | +33.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRoche reported that investigational sefaxersen, an Ionis-partnered drug, produced a statistically significant 43.1% reduction in protein in the urine among adults with primary IgA nephropathy, a kidney disease, in the ongoing Phase 3 IMAgINATION study. The result was described as clinically meaningful, with a 95% confidence interval of 32.5% to 52.0%; the excerpt does not provide the full P-value, safety findings or other study outcomes.
Roche reported that investigational sefaxersen reduced proteinuria, a key measure of kidney damage, by 43.1% versus placebo at 37 weeks in the ongoing Phase 3 IMAgINATION study for IgA nephropathy. The result was statistically significant and consistent across prespecified patient groups, but the drug is not yet approved.
Science named Ionis Pharmaceuticals the No. 1 employer to work for in its annual biotech and pharmaceutical survey, up from No. 2 last year. This was Ionis’s second year of eligibility, and the recognition cited its innovation, talented employees, and values-based culture.
Ionis Pharmaceuticals received FDA orphan drug designation, a status for treatments addressing rare diseases, for a therapy targeting a rare form of epilepsy. The treatment targets the SCN1A gene, which is involved in producing a brain protein that regulates electrical activity and helps prevent seizures.
BMO Capital Markets upgraded Ionis Pharmaceuticals (IONS) from a "market perform" rating to an "outperform" rating and set a $66 price objective. The article says IONS shares were lifted but identifies no operational or financial catalyst beyond the analyst action.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | B- | $6.00B | — | 0.32 | Compare |
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| ERAS | Erasca, Inc. | C | $5.21B | — | 0.66 | Compare |
| ARWR | Arrowhead Pharmaceuticals, Inc. | C+ | $8.71B | — | 1.39 | Compare |
| CYTK | Cytokinetics, Incorporated | B+ | $8.84B | — | 0.40 | Compare |
| KRYS | Krystal Biotech, Inc. | B | $9.21B | 38.12 | 0.71 | Compare |
| TWST | Twist Bioscience Corporation | D | $9.24B | — | 2.30 | Compare |
| MDGL | Madrigal Pharmaceuticals, Inc. | B | $9.25B | — | -1.03 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.